Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 274

1.

Successful management of chronic gastrointestinal hemorrhage using bevacizumab in the setting of hereditary hemorrhagic telangiectasia.

Sehl ME, M Gruber T, McWilliams JP, Marder VJ.

Am J Hematol. 2015 Jun;90(6):561-3. doi: 10.1002/ajh.23969. Epub 2015 May 10. No abstract available.

2.

Direct microscopic monitoring of initial and dynamic clot lysis using plasmin or rt-PA in an in vitro flow system.

Bizjak N, Bajd F, Vidmar J, Blinc A, Perme MP, Marder VJ, Novokhatny V, Serša I.

Thromb Res. 2014 May;133(5):908-13. doi: 10.1016/j.thromres.2014.02.008. Epub 2014 Feb 22.

PMID:
24613694
3.

Single-nucleotide variations defining previously unreported ADAMTS13 haplotypes are associated with differential expression and activity of the VWF-cleaving protease in a Salvadoran congenital thrombotic thrombocytopenic purpura family.

Kim B, Hing ZA, Wu A, Schiller T, Struble EB, Liuwantara D, Kempert PH, Broxham EJ, Edwards NC, Marder VJ, Simhadri VL, Sauna ZE, Howard TE, Kimchi-Sarfaty C.

Br J Haematol. 2014 Apr;165(1):154-8. doi: 10.1111/bjh.12713. Epub 2014 Jan 16. No abstract available.

PMID:
24433405
4.

Comparison of local thrombolytic efficacy of plasmin and rt-PA in an in-vitro flow system; a pilot study.

Bizjak N, Bajd F, Vidmar J, Blinc A, Marder VJ, Novokhatny V, Serša I.

Blood Coagul Fibrinolysis. 2013 Oct;24(7):711-4. doi: 10.1097/MBC.0b013e328361bd48.

PMID:
23751605
5.

Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.

Harenberg J, Marx S, Dahl OE, Marder VJ, Schulze A, Wehling M, Weiss C.

Thromb Haemost. 2012 Nov;108(5):903-12. doi: 10.1160/TH12-07-0482. Epub 2012 Sep 26.

PMID:
23014668
6.

Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.

Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.

Int Angiol. 2012 Aug;31(4):330-9. Review.

PMID:
22801398
7.

Safety evaluation of a recombinant plasmin derivative lacking kringles 2-5 and rt-PA in a rat model of transient ischemic stroke.

Crumrine RC, Marder VJ, Taylor GM, LaManna JC, Tsipis CP, Novokhatny V, Scuderi P, Petteway SR Jr, Arora V.

Exp Transl Stroke Med. 2012 May 16;4(1):10. doi: 10.1186/2040-7378-4-10.

8.

Interference of thrombin in immunological assays for hirudin specific antibodies.

Hamilton RG, Levy JH, Marder VJ, Sane DC.

J Immunol Methods. 2012 Jul 31;381(1-2):50-8. doi: 10.1016/j.jim.2012.04.008. Epub 2012 Apr 20.

PMID:
22542931
9.

Safety of catheter-delivered plasmin in patients with acute lower extremity arterial or bypass graft occlusion: phase I results.

Marder VJ, Comerota AJ, Shlansky-Goldberg RD, Davis JP, Deng C, Hanna K, Fineberg D.

J Thromb Haemost. 2012 Jun;10(6):985-91. doi: 10.1111/j.1538-7836.2012.04728.x.

10.

Glomerular hemophagocytic macrophages in a patient with proteinuria and clinical and laboratory features of hemophagocytic lymphohistiocytosis (HLH).

Cao L, Wallace WD, Eshaghian S, Linhares Y, Marder VJ.

Int J Hematol. 2011 Nov;94(5):483-7. doi: 10.1007/s12185-011-0936-2. Epub 2011 Nov 1.

PMID:
22038068
11.

Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model.

Crumrine RC, Marder VJ, Taylor GM, Lamanna JC, Tsipis CP, Scuderi P, Petteway SR Jr, Arora V.

Exp Transl Stroke Med. 2011 Sep 20;3(1):10. doi: 10.1186/2040-7378-3-10.

12.

Ancrod and fibrin formation: perspectives on mechanisms of action.

Liu S, Marder VJ, Levy DE, Wang SJ, Yang F, Paganini-Hill A, Fisher MJ.

Stroke. 2011 Nov;42(11):3277-80. doi: 10.1161/STROKEAHA.111.622753. Epub 2011 Aug 25.

13.

Historical perspective and future direction of thrombolysis research: the re-discovery of plasmin.

Marder VJ.

J Thromb Haemost. 2011 Jul;9 Suppl 1:364-73. doi: 10.1111/j.1538-7836.2011.04370.x. Review.

14.

Comparison of plasmin with recombinant tissue-type plasminogen activator in lysis of cerebral thromboemboli retrieved from patients with acute ischemic stroke.

Marder VJ, Blinc A, Gruber T, Tratar G, Sabovic M, Starkman S, Jahan R, Duckwiler G, Vinuela F, Tateshima S, Liebeskind D, Ovbiagele B, Ali L, Kim D, Gonzalez N, Vespa PM, Saver JL.

Stroke. 2011 Aug;42(8):2222-8. doi: 10.1161/STROKEAHA.110.609198. Epub 2011 Jun 23.

15.

CT and MRI early vessel signs reflect clot composition in acute stroke.

Liebeskind DS, Sanossian N, Yong WH, Starkman S, Tsang MP, Moya AL, Zheng DD, Abolian AM, Kim D, Ali LK, Shah SH, Towfighi A, Ovbiagele B, Kidwell CS, Tateshima S, Jahan R, Duckwiler GR, Viñuela F, Salamon N, Villablanca JP, Vinters HV, Marder VJ, Saver JL.

Stroke. 2011 May;42(5):1237-43. doi: 10.1161/STROKEAHA.110.605576. Epub 2011 Mar 10.

16.

Thrombolysis with plasmin: implications for stroke treatment.

Marder VJ, Jahan R, Gruber T, Goyal A, Arora V.

Stroke. 2010 Oct;41(10 Suppl):S45-9. doi: 10.1161/STROKEAHA.110.595157.

17.

Haemostatic safety of a unique recombinant plasmin molecule lacking kringles 2-5.

Marder VJ, Manyak S, Gruber T, Goyal A, Moreno G, Hunt J, Bromirski J, Scuderi P, Petteway SR Jr, Novokhatny V.

Thromb Haemost. 2010 Oct;104(4):780-7. doi: 10.1160/TH09-10-0742. Epub 2010 Aug 30.

PMID:
20806125
18.

Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization.

Warkentin TE, Cook RJ, Marder VJ, Greinacher A.

J Thromb Haemost. 2010 Mar;8(3):504-12. doi: 10.1111/j.1538-7836.2009.03735.x. Epub 2009 Dec 24.

19.

Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential.

Marder VJ, Novokhatny V.

J Thromb Haemost. 2010 Mar;8(3):433-44. doi: 10.1111/j.1538-7836.2009.03701.x. Epub 2009 Nov 23. Review.

20.

Thrombolytic therapy for deep vein thrombosis: potential application of plasmin.

Marder VJ.

Thromb Res. 2009;123 Suppl 4:S56-61. doi: 10.1016/S0049-3848(09)70145-8. Review.

PMID:
19303506
21.

On the significance of marginally low von Willebrand factor.

Onundarson PT, Gudmundsdottir BR, Marder VJ.

Thromb Haemost. 2008 Dec;100(6):1213-4. No abstract available.

PMID:
19132256
22.

Pre-clinical studies of plasmin: superior benefit-to-risk ratio of plasmin compared to tissue plasminogen activator.

Marder VJ.

Thromb Res. 2008;122 Suppl 3:S9-S15. doi: 10.1016/j.thromres.2008.06.019. Epub 2008 Aug 22. Review.

23.

A first-in-human phase I trial of locally delivered human plasmin for hemodialysis graft occlusion.

Shlansky-Goldberg RD, Matsumoto AH, Baumbach GA, Siegel JB, Raabe RD, Murphy TP, Deng C, Ray Dawkins J, Marder VJ.

J Thromb Haemost. 2008 Jun;6(6):944-50. doi: 10.1111/j.1538-7836.2008.02969.x. Epub 2008 Apr 2.

24.

Middle cerebral artery occlusion in the rabbit using selective angiography: application for assessment of thrombolysis.

Jahan R, Stewart D, Vinters HV, Yong W, Vinuela F, Vandeberg P, Marder VJ.

Stroke. 2008 May;39(5):1613-5. doi: 10.1161/STROKEAHA.107.507376. Epub 2008 Mar 13.

25.

Risk of excessive bleeding associated with marginally low von Willebrand factor and mild platelet dysfunction.

Gudmundsdottir BR, Marder VJ, Onundarson PT.

J Thromb Haemost. 2007 Feb;5(2):274-81. Epub 2006 Nov 29.

26.

Magnesium sulfate neither potentiates nor inhibits tissue plasminogen activator-induced thrombolysis.

Stewart D, Marder VJ, Starkman S, Saver JL.

J Thromb Haemost. 2006 Jul;4(7):1575-9.

27.

Analysis of thrombi retrieved from cerebral arteries of patients with acute ischemic stroke.

Marder VJ, Chute DJ, Starkman S, Abolian AM, Kidwell C, Liebeskind D, Ovbiagele B, Vinuela F, Duckwiler G, Jahan R, Vespa PM, Selco S, Rajajee V, Kim D, Sanossian N, Saver JL.

Stroke. 2006 Aug;37(8):2086-93. Epub 2006 Jun 22.

PMID:
16794209
28.

Conference summary and recommendations for research.

Hasan AA, Marder VJ.

Thromb Res. 2005;117(1-2):229-30. Epub 2005 Oct 12. No abstract available.

PMID:
16225912
29.

Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.

Warkentin TE, Cook RJ, Marder VJ, Sheppard JA, Moore JC, Eriksson BI, Greinacher A, Kelton JG.

Blood. 2005 Dec 1;106(12):3791-6. Epub 2005 Aug 18.

30.

Opinions and research priorities.

Bussey HI, Tapson V, Cannon RO 3rd, Nolan PE Jr, Gage B, Penzak SR, Spinler SA, De Smet P, Wittkowsky A, Lee AP, Ernst E, Marder VJ.

Thromb Res. 2005;117(1-2):155-69; discussion 170-4. Epub 2005 Aug 15. No abstract available.

PMID:
16099491
31.

The interaction of dietary supplements with antithrombotic agents: scope of the problem.

Marder VJ.

Thromb Res. 2005;117(1-2):7-13; discussion 39-42. Epub 2005 Aug 1. Review. No abstract available.

PMID:
16076481
32.

Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No.

Rickles FR, Marder VJ.

J Thromb Haemost. 2005 May;3(5):842-3. No abstract available.

33.

Quantitative assessment of thrombus burden predicts the outcome of treatment for venous thrombosis: a systematic review.

Hull RD, Marder VJ, Mah AF, Biel RK, Brant RF.

Am J Med. 2005 May;118(5):456-64. Review.

PMID:
15866245
34.

Foundation and sites of action of antithrombotic agents.

Marder VJ, Rosove MH, Minning DM.

Best Pract Res Clin Haematol. 2004 Mar;17(1):3-22. Review.

PMID:
15171955
35.

Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?

Novokhatny VV, Jesmok GJ, Landskroner KA, Marder VJ, Zimmerman TP.

Trends Pharmacol Sci. 2004 Feb;25(2):72-5. Review.

PMID:
15102492
36.

Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction.

Narins CR, Zareba W, Moss AJ, Marder VJ, Ridker PM, Krone RJ, Lichstein E.

Arch Intern Med. 2004 Feb 23;164(4):440-6.

PMID:
14980996
37.

Safety of plasmin in the setting of concomitant aspirin and heparin administration in an animal model of bleeding.

Sadeghi S, Marder VJ, Stewart D, Kong M, Humphries J, Baumbach GA, Jesmok G.

J Thromb Haemost. 2003 Dec;1(12):2621-5.

38.

Metabolic syndrome best defines the multivariate distribution of blood variables in postinfarction patients.

Corsetti JP, Zareba W, Moss AJ, Ridker PM, Marder VJ, Rainwater DL, Sparks CE.

Atherosclerosis. 2003 Dec;171(2):351-8.

PMID:
14644407
39.
40.

Life-threatening thrombotic thrombocytopenic purpura (TTP) in a patient with sickle cell-hemoglobin C disease.

Lee HE, Marder VJ, Logan LJ, Friedman S, Miller BJ.

Ann Hematol. 2003 Nov;82(11):702-4. Epub 2003 Aug 16.

PMID:
12923661
41.

Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparin.

Chan S, Kong M, Minning DM, Hedner U, Marder VJ.

J Thromb Haemost. 2003 Apr;1(4):760-5.

42.

Association between inflammatory markers, hemostatic, and lipid factors in postinfarction patients.

Harb TS, Zareba W, Moss AJ, Ridker PM, Rifai N, Marder VJ, Miller-Watelet L; THROMBO Investigators.

Am J Cardiol. 2003 May 1;91(9):1120-3. No abstract available.

PMID:
12714160
43.

History of hypertension and enhanced thrombogenic activity in postinfarction patients.

Fadl YY, Zareba W, Moss AJ, Marder VJ, Sparks CS, Miller Watelet LF, Carroll ER.

Hypertension. 2003 Apr;41(4):943-9. Epub 2003 Mar 10.

PMID:
12629034
44.

Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage.

Stewart D, Kong M, Novokhatny V, Jesmok G, Marder VJ.

Blood. 2003 Apr 15;101(8):3002-7. Epub 2002 Nov 21.

45.

Towards safer thrombolytic therapy.

Marder VJ, Stewart D.

Semin Hematol. 2002 Jul;39(3):206-16. Review.

PMID:
12124683
46.

Maximized hemostasis.

Marder VJ.

Thromb Haemost. 2002 Apr;87(4):555-6. No abstract available.

PMID:
12008934
47.

Use of thrombolytic therapy for acute myocardial infarction: effects of gender and age on treatment rates.

Kaplan KL, Fitzpatrick P, Cox C, Shammas NW, Marder VJ.

J Thromb Thrombolysis. 2002 Feb;13(1):21-6.

PMID:
11994556
48.

Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction.

Harb TS, Zareba W, Moss AJ, Ridker PM, Marder VJ, Rifai N, Miller Watelet LF, Arora R, Brown MW, Case RB, Dwyer EM Jr, Gillespie JA, Goldstein RE, Greenberg H, Hochman J, Krone RJ, Liang CS, Lichstein E, Little W, Marcus FI, Oakes D, Sparks CE, VanVoorhees L; THROMBO Investigators.

Am J Cardiol. 2002 Jan 15;89(2):216-21. No abstract available.

PMID:
11792346
49.

Thrombolytic therapy: 2001.

Marder VJ.

Blood Rev. 2001 Sep;15(3):143-57. Review. No abstract available.

PMID:
11735162
50.

Orally active heparin and low-molecular-weight heparin.

Pineo GF, Hull RD, Marder VJ.

Curr Opin Pulm Med. 2001 Sep;7(5):344-8. Review.

PMID:
11584187

Supplemental Content

Loading ...
Support Center